Compare Illumina, Inc. (ILMN) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Mondaycom Ltd — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Mondaycom Ltd trades at $75.09 (market cap $3.24B). The key difference: Illumina, Inc. is far larger — about 8.6× Mondaycom Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | MNDY | |
|---|---|---|
Market Cap | $27.94B | $3.24B |
Sector | Health | Technology |
52-Week High | $194.33 | $292.24 |
52-Week Low | $91.00 | $58.81 |
Enterprise Value | $29.33B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Monday.com trades at $76.75, down 2.47% on the day, with technical indicators showing neutral signals. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 beating expectations of $0.96. Revenue grew to $1.23 billion in 2025 with a healthy 89.05% gross margin. Analyst sentiment remains bullish with 76% buy ratings and a $115.50 consensus price target representing 50% upside potential. Recent news highlights institutional selling but positive coverage of the company's AI-driven work management platform.
The stock presents a compelling opportunity given its strong earnings track record, high analyst conviction, and attractive valuation discount to price targets. Key risks include competitive pressures in the SaaS space and the stock's high valuation multiples. The company's transition to a 'seats + credits' pricing model and AI integration provide growth catalysts, though investors should monitor execution against 2026 guidance and cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
